Table 3.

Analyses of prognostic factors for survival.

Factor	Overall survival				Progression-free survival
	Univariate analysis		Multivariate analysis		Univariate analysis		Multivariate analysis
	HR(95%CI)	P value	HR(95%CI)	P value	HR(95%CI)	P value	HR(95%CI)	P value
Treatment option
T+L+C/T+C/TACE	0.47(0.38-0.60)	<0.001	0.49(0.39-0.62)	<0.001	0.57(0.46-0.71)	<0.001	0.59(0.48-0.73)	<0.001
Age	0.99(0.97-1.01)	0.297			1.00(0.98-1.02)	0.751
Sex
Female/Male	0.79(0.48-1.29)	0.346			0.66(0.42-1.03)	0.069	0.80(0.50-1.27)	0.342
Etiology
Hepatitis B/Others	1.31(0.81-2.12)	0.273			1.21(0.78-1.87)	0.392
Cirrhosis
Yes/No	1.10(0.70-1.73)	0.687			1.22(0.80-1.86)	0.362
ECOG PS score
2/1	0.98(0.65-1.49)	0.929			1.08(0.73-1.58)	0.711
Child-Pugh class
B/A	1.26(0.65-2.44)	0.493			1.05(0.56-1.95)	0.889
ALBI grade
3/2/1	1.00(0.69-1.45)	0.983			0.97(0.69-1.37)	0.851
portal vein invasion
Yes/No	2.62(1.69-4.05)	<0.001	2.54(1.63-3.94)	<0.001	2.46(1.67-3.62)	<0.001	2.46(1.67-3.62)	<0.001
Extrahepatic metastasis
Yes/No	1.07(0.71-1.62)	0.754			1.10(0.76-1.62)	0.610
Number of tumors
3/2/1	1.04(0.84-1.27)	0.749			0.98(0.81-1.18)	0.803
Largest tumor size (cm)
≥10/<10	1.00(1.00-1.01)	0.425			1.00(1.00-1.01)	0.499
AFP level (μg/L)
≥400/<400	1.25(0.84-1.85)	0.278			1.11(0.78-1.60)	0.563

Analyses were performed using Cox proportional hazard regression model. HR, hazard ratio; CI, confidence interval; T+L+C, transarterial chemoembolization combined with lenvatinib plus camrelizumab; T+C, transarterial chemoembolization combined with camrelizumab; TACE, transarterial chemoembolization; ECOG-PS, Eastern Cooperative Oncology Group performance status; AFP, alpha-fetoprotein. HR and P values that are meaningful for multivariate analyses are in bold; bold is for eye-catching.